Here's your US review and approval news for the week in brief: It didn't take the Food and Drug Administration long to approve the first novel drug of 2020 (and the new decade), with the honor going to Blueprint Medicines Corp.'s targeted gastrointestinal stromal tumor (GIST) drug Ayvakit (avapritinib).
A notable supplemental approval went to Merck & Co. Inc.'s PD-1 inhibitor Keytruda (pembrolizumab) for a high-risk bladder cancer...





